Adaptimmune Therapeutics Stock Discussion

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...

$Adaptimmune Therapeutics (ADAP.US)$ .. green when is the pre-market , will drop once open market!!!

$Adaptimmune Therapeutics (ADAP.US)$ Item 1.01Entry into a Material Definitive Agreement.
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...

$Adaptimmune Therapeutics (ADAP.US)$
so the spike in cash is from financing, fyi

20% before didn't TP. will wait patiently... or maybe CL...
after the product is approved, profitable, it's your time to shine.
$Adaptimmune Therapeutics (ADAP.US)$

hhh not happening for $Adaptimmune Therapeutics (ADAP.US)$
come on